Extended Data Fig. 7: C26-A6 treatment elevates immune responses in tumors.
a, The correlation between all the gene sets that alters by Mtdh acute loss and C26-A6 treatment. b,c, Py8119-OVA cells co-cultured with OT-I splenocytes were treated with 200 μM of C26-A6 or same amount of vehicle. The binding between SND1 and Tap1/2 in tumor cells were determined by RIP assay (b). Tap1/2 RNAs that bind to SND1 were quantified and normalized to the pulled down SND1 levels (c). d, MHC-I presentation in Py8119-OVA cells with/without 200 μM of C26-A6 treatment in co-culture were determined by flow cytometry. MFI, mean fluorescence intensity; AU, arbitrary units. e,f, The expression of CD137 and IFN-γ in splenocytes co-cultured with Py8119-OVA were determined by flow cytometry upon 200 μM of C26-A6 or vehicle treatment. MFI, Mean Fluorescence Intensity; AU, arbitrary units. In panels from b-f, data represent mean ± SEM. n = 3 independent experiments. Significance determined by two tailed Student’s t-test. Numerical source data for a, c-f and uncropped images for b are provided.
